MDS - 113
Updated Overall Survival (OS) and Long-Term Transfusion Independence (TI) From the Phase 3 COMMANDS Trial in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Guillermo Garcia-Manero
Poster Presenter: Guillermo Garcia-Manero
